U.S. markets close in 3 hours 19 minutes

Passage Bio, Inc. (PASG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6365-0.0225 (-3.41%)
As of 12:36PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.6590
Bid0.6374 x 3000
Ask0.6394 x 1400
Day's Range0.6300 - 0.6580
52 Week Range0.6300 - 1.9200
Avg. Volume175,238
Market Cap34.887M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-2.0300
Earnings DateNov 08, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PASG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Passage Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/26/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference

    PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET. A live webcast of the event will be available on the Investors & Media

  • Simply Wall St.

    Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

    Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-20